AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination
29/09/2026 01:16
AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination Sept 29 (Reuters) - HUTCHMED (China) 0013.HK said on Tuesday Anglo-Swedish drugmaker AstraZeneca AZN.L had filed an application with the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination in patients with advanced lung cancer.
ORPATHYS is being jointly developed by AstraZeneca and HUTCHMED and is commercialised by AstraZeneca.
(Reporting by Roshan Thomas in Bengaluru; Editing by Subhranshu Sahu)
Recent news on AstraZeneca
See all newsAstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
Early US flu season, current strain may signal risk for younger people; doctors urge shots
AstraZeneca partners with Oracle for AI-driven clinical trials
Factbox: Pharma sector doubles down on AI to slash costs, timelines